Negative phase 3 study of 90Y microspheres versus sorafenib in HCC

Negative phase 3 study of ⁹⁰Y microspheres versus sorafenib in HCC

Lancet Oncol. 2018 Feb;19(2):e70. doi: 10.1016/S1470-2045(18)30024-X.

¹ Department of Nuclear Medicine, Cancer Institute Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042 Rennes cedex, France; University of Rennes 1, 35033 Rennes, France; INSERM, INRA, Univ Rennes 1, Univ Bretagne Loire, Nutrition Metabolism and Cancer (NuMeCan), Rennes, France. Electronic address: [email protected].
² Department of Medical Imaging, Cancer Institute Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042 Rennes cedex, France; U 1099, INSERM, Rennes, France; LTSI, Université de Rennes 1, Rennes, France.
³ Clinical Research Direction, Cancer Institute Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042 Rennes cedex, France.
⁴ Department of Medical Oncology, Cancer Institute Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042 Rennes cedex, France; University of Rennes 1, 35033 Rennes, France; INSERM, INRA, Univ Rennes 1, Univ Bretagne Loire, Nutrition Metabolism and Cancer (NuMeCan), Rennes, France.

No abstract available